NADI-351 is an orally active and potent Notch1 inhibitor that selectively disrupts Notch1 transcription complexes and reduces Notch1 recruitment to target genes. NADI-351 can be utilized in cancer research.
Products | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Notch
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.